Is Thymosin Alpha-1 Legal in Louisiana? How to Access It Legally

Print or save as PDF

  • FDA status / Not approved; four orphan designations are not approvals [1]
  • State-licensed pharmacy list / In none of the three categories, updated May 14, 2026 [2]
  • Outsourcing facility list / Category 3, nominated without adequate support [3]
  • Advisory committee vote / 4 yes, 17 no on December 4, 2024 [4]
  • HHS draft peptide policy / Not one of the six peptides included [5]
  • Approved outside the US / Zadaxin in Italy, India and Hong Kong [1]

Is thymosin alpha-1 FDA-approved?

No. A Drugs@FDA search found no US application for thymosin alpha-1 (thymalfasin). FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process and is not an approval. [1]

What does FDA say about compounding?

For state-licensed pharmacies and physicians, thymosin alpha-1 is in none of the three categories on FDA's list updated May 14, 2026. [2] For outsourcing facilities, it is in category 3, 'nominated without adequate support', on FDA's list updated March 21, 2025. FDA's category 1 policy, which generally says no action against compounders if conditions are met, does not apply to it. [3]

FDA proposed that thymosin alpha-1 not be added to the pharmacy bulks list. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access. [4]

Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500). We found no FDA or HHS action allowing compounding of thymosin alpha-1. [5]

What is approved outside the US?

Zadaxin is the brand of the finished injection sold outside the US, 1.6 mg per vial; it is not interchangeable with bulk thymosin alpha-1 powder. [1] FDA lists approvals in Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and in Hong Kong. [1]

Two older reviews, both from authors tied to the Zadaxin developer, say it is approved in more than 30 countries (2007) and over 35 countries (2009). [7][8] A SciClone 2014 annual report describes approvals in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, mostly for hepatitis B and as a vaccine adjuvant; FDA said it could not independently verify those broader claims. [1]

What safety concerns are posted?

Thymosin alpha-1 was previously in category 2 (significant safety risks) of FDA's bulk-substance list and now sits in the 'nominated but withdrawn' table, because the nominators withdrew it. FDA's concerns remain posted: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information that FDA called inadequate 'for the agency to sufficiently understand the extent of any safety issues'. [9]

FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1. [1] In a 2026 Cochrane review of hepatitis B trials, thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence). The reviewers said they were 'not sure' thymosin alpha-1 helps in hepatitis B. [10]

What about Louisiana?

The FDA and HHS documents on this page do not address Louisiana state law, so they cannot show whether Louisiana permits a pharmacy or prescriber to supply thymosin alpha-1. No Louisiana-specific access route is supported here.

At the federal level, thymosin alpha-1 is not FDA-approved, it is in none of the three categories on the state-licensed pharmacy list, and it is in category 3 for outsourcing facilities. The advisory committee voted 4 to 17 against adding it to the pharmacy bulks list. [1][2][3][4]

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Is Zadaxin interchangeable with bulk thymosin alpha-1 powder, according to the article?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is thymosin alpha-1 legal in Louisiana?
Thymosin alpha-1 is not FDA-approved. It does not appear in any of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is in category 3 on the list for outsourcing facilities. The federal documents do not address Louisiana state law, so no Louisiana-specific access route can be confirmed from them. [1][2][3]
Can a Louisiana pharmacy compound thymosin alpha-1?
FDA's list for state-licensed pharmacies and physicians places it in none of the three categories, updated May 14, 2026, and FDA's category 1 policy does not apply to it. We found no FDA or HHS action allowing it to be compounded. [2][3][5]
Can an outsourcing facility supply it?
It is in category 3, nominated without adequate support, on FDA's outsourcing-facility list updated March 21, 2025. FDA's category 1 policy does not apply. [3]
Is it approved in any country?
FDA lists Zadaxin approvals in Italy, India and Hong Kong. Zadaxin is the finished 1.6 mg injection sold outside the US and is not interchangeable with bulk powder. [1]
Did FDA consider adding it to the pharmacy bulks list?
Yes. FDA proposed that it not be added. The Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on December 4, 2024, on both the free base and the acetate. [4]
What safety concerns does FDA list?
FDA lists significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information it called inadequate to understand the extent of any safety issues. [9]
Show all 10 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Louisiana? How to Access It Legally